Hopefully today's movement was due to analysts finally realizing that MNTA has a winner in enoxaparin rather than this PR...
Momenta Pharmaceuticals Announces M118 Selected as a "Top 10 Cardiovascular/Metabolic Projects to Watch" Windhover Expert Panel
infolink
CAMBRIDGE, Mass., Oct. 26, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that its next-generation novel drug candidate, M118, was selected by an expert panel from Windhover Information and the publishers of In Vivo and Startup as one of its "Top 10 CV/Metabolic Projects to Watch".
Criteria for the "Top 10" designation included:
Large market, large unmet need, with increasing opportunity
History of the molecule and drug
Strong science
Strong company
Diversity of indications
Potential for new opportunities beyond the initial indications
Multi-level partnering opportunities
"We believe this recognition supports the considerable promise of our novel anticoagulant drug candidate M118 in patients with acute coronary syndromes for both medical management and in the peri-procedural setting," stated Jim Roach, M.D, SVP and Chief Medical Officer of Momenta. "M118, a low-molecular-weight heparin, was rationally designed to capture the positive attributes of both unfractionated heparin and enoxaparin in one compound. We have reported positive results from our 500 patient Phase 2a clinical trial in patients with ACS undergoing elective percutaneous coronary intervention, and look forward to finding a suitable collaborative partner to continue development of M118 in ACS."
[snip] |
